UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
11-K
FOR
ANNUAL REPORTS OF
EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS
PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
(MARK
ONE)
☒ ANNUAL
REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020
OR
☐ TRANSITION
REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR
THE TRANSITION PERIOD FROM ______________ TO ____________
COMMISSION
FILE NUMBER 001-09974
Enzo
Biochem, Inc.
Salary Reduction Profit Sharing Plan
(Full
title of the plan and the address of the plan, if different from that of the issuer named below:)
Enzo
Biochem, Inc. 527 Madison Ave. New York, NY 10022
(Name
of issuer of the securities held pursuant to the plan and the address of its principal executive office)
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Table
of Contents
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Plan Administrator, Participants and Beneficiaries of the
Enzo
Biochem, Inc. Salary Reduction Profit Sharing Plan
Opinion
on the Financial Statements
We
have audited the accompanying statements of net assets available for benefits of the Enzo Biochem, Inc. Salary Reduction Profit Sharing
Plan (the “Plan”) as of December 31, 2020 and 2019, and the related statement of changes in net assets available for benefits
for the year ended December 31, 2020, and the related notes (collectively the “financial statements”). In our opinion, the
financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2020
and 2019, and the changes in net assets available for benefits for the year ended December 31, 2020, in conformity with accounting principles
generally accepted in the United States of America.
Basis
for Opinion
These
financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.
Report
on Supplemental Information
The
supplemental information in the accompanying schedule of assets (held at end of year) as of December 31, 2020 has been subjected to audit
procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility
of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial
statements or underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy
of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether
the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and
Regulations for Reporting Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information
is fairly stated, in all material respects, in relation to the financial statements as a whole.
/s/
EisnerAmper LLP
We
have served as the Plan’s auditor since 2010.
EISNERAMPER
LLP
New
York, New York
June
25, 2021
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Statements
of Net Assets Available for Benefits
December
31,
|
|
2020
|
|
|
2019
|
|
ASSETS
|
|
|
|
|
|
|
Investments, at fair value:
|
|
|
|
|
|
|
Mutual funds
|
|
$
|
38,527,638
|
|
|
$
|
32,523,374
|
|
Enzo Biochem, Inc. common stock
|
|
|
3,376,713
|
|
|
|
2,961,454
|
|
|
|
|
41,904,351
|
|
|
|
35,484,828
|
|
Receivables:
|
|
|
|
|
|
|
|
|
Employer’s contributions
|
|
|
779,927
|
|
|
|
836,494
|
|
Notes receivable – participants
|
|
|
582,320
|
|
|
|
766,493
|
|
|
|
|
1,362,247
|
|
|
|
1,602,987
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
43,266,598
|
|
|
|
37,087,815
|
|
|
|
|
|
|
|
|
|
|
NET ASSETS AVAILABLE FOR BENEFITS
|
|
$
|
43,266,598
|
|
|
$
|
37,087,815
|
|
See
notes to financial statements.
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Statement
of Changes in Net Assets Available for Benefits
For
the Year Ended December 31, 2020
Additions (deductions) from net assets attributed to:
|
|
|
|
Investment income:
|
|
|
|
Interest and dividends
|
|
$
|
2,095,186
|
|
Net realized/unrealized appreciation in value of investments
|
|
|
3,851,584
|
|
Interest on notes receivable - participants
|
|
|
32,531
|
|
Contributions:
|
|
|
|
|
Participants’ contributions
|
|
|
2,221,592
|
|
Employer’s contributions
|
|
|
779,927
|
|
Benefits paid to participants
|
|
|
(2,746,072
|
)
|
Administrative expenses
|
|
|
(55,965
|
)
|
Net increase in net assets available for benefits
|
|
|
6,178,783
|
|
|
|
|
|
|
Net assets available for benefits, beginning of year
|
|
|
37,087,815
|
|
|
|
|
|
|
Net assets available for benefits, end of year
|
|
$
|
43,266,598
|
|
See
notes to financial statements.
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
The
following description of the Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan (the “Plan”) provides only general information.
Participants should refer to the Plan Agreement, as amended, for a more complete description of the Plan’s provisions.
General
The
Plan is a defined contribution plan covering all eligible United States based full-time employees of Enzo Biochem, Inc., (the “Plan
Sponsor”), and its wholly owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Therapeutics, Inc., and Enzo Life Sciences, Inc. (collectively,
the “Company”) who have completed one month of service and have attained age twenty-one. The Plan is subject to
the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”).
Contributions
Eligible
employee participants can elect to defer up to 70% of compensation to the maximum amount permitted by the Internal Revenue Code (the
“Code”) for each year ($19,500 in 2020 and $19,000 in 2019). Catch-up contributions are also permitted for participants who
have attained age 50 by December 31st, in accordance with Section 414(v) of the Code, in an amount up to a maximum of $6,500
in 2020 and $6,000 in 2019, bringing those participants’ statutory maximum limitation to $26,000 in 2020 and $25,000 in 2019. In
2020, participant contributions totaled $2,221,592 which includes $61,000 in rollover contributions.
The
Company may contribute to the Plan annually, a discretionary matching contribution and a non-elective employer contribution. For 2020
and 2019 the discretionary matching contribution was equal to 50% of the participant’s 401(k) contribution, not to exceed 5% of
the participant’s annual compensation, as defined. Participants who have completed 1,000 hours of service during the plan year
and are actively employed as of the last day of the plan year shall be deemed eligible to share in the matching contribution or the non-elective
employer contribution for the year. In 2020, the total matching contributions were $779,927 in the form of Enzo Biochem Inc. common stock. There
were no non-elective employer contributions made in 2020 or 2019.
The
Plan provides that unless the participant affirmatively elects otherwise, the participant’s compensation will automatically be
reduced by 3%, which will be considered to be the Participant’s salary reduction election.
Participant
Accounts
Participants
direct both their contributions and employer contributions into various investment options offered by the Plan which include a choice
of mutual funds and the common stock of Enzo Biochem, Inc. Each participant’s account is credited with the participant’s
contribution and allocations of (a) the Company’s matching contribution and non-elective employer contribution, (b) Plan earnings
and c) charged with an allocation of administrative expenses. Allocations are based on participant compensation, account balances or
specific participant transactions, as defined. The benefit to which a participant is entitled is the benefit that can be provided from
the participant’s vested account. The Plan allows a participant to elect to classify all or part of his or her elective deferrals
as a Roth 401(k) deferral.
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
Vesting
Participants’
contributed funds arising from salary reductions and the earnings thereon, are fully vested at all times. Vesting in the Company’s
discretionary matching contribution and non-elective employer contribution and earnings thereon, is ratable over four years of service.
Forfeitures
Forfeited
non-vested amounts may be used to reduce the Company’s future contributions to the Plan or pay Plan expenses. During the year ended
December 31, 2020, forfeitures were used to pay $38,095 of Plan expenses. Forfeited non-vested amounts available at December 31, 2020
and 2019 were $18,713 and $33,316, respectively.
Notes
Receivable from Participants
Notes
receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Participants
may borrow from their accounts a minimum of $1,000 up to a maximum of 50% of their vested account balance or $50,000. Participants are
entitled to borrow from their account for a maximum loan term of five years unless the proceeds are used to acquire a principal residence
in which case it may exceed five years. The loans, classified as Notes Receivable from Participants, are secured by the participant’s
vested account balance and bear a reasonable rate of interest, ranging from 4.5% to 5.0% at December 31, 2020. Principal and interest
is paid ratably through payroll deductions. Delinquent notes receivable from participants are reclassified as distributions based upon
the terms of the Plan document. Related fees are recorded as administrative expenses and are expensed when they are incurred.
The
Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was signed into law on March 27, 2020 and provided certain loan
provisions. Participants, who meet specific conditions, are eligible to take a COVID-19 related loan up to $100,000 (an increase from
$50,000 previously allowed) for the period March 27, 2020 to September 22, 2020. Loan repayments due between March 27, 2020 and December
31, 2020 may be suspended until January 1, 2021 for eligible participants, with the repayment amount re-amortized and the due date of
the loan extended for up to one year.
Payment
of Benefits
On
termination of service due to death, disability or retirement, participants may elect to receive an amount equal to the value of the
vested interest in their account in a lump sum amount. For termination of service due to other reasons, a participant may
receive the value of the vested interest in their account as a lump sum distribution. Benefits are payable in the form of cash or Company
common stock.
The Cares Act also provided optional distribution as well as
suspension of required minimum distributions (“RMDs”) for anyone required to receive an RMD in 2020. The Plan Sponsor has
implemented the following provisions of the CARES Act and the Plan will be formally amended prior to December 31, 2022 as required by
the Act.
Participants, who meet specific conditions, are eligible to
take a COVID-19 related distribution up to $100,000 without a 10% early withdrawal penalty. Eligible distributions can be taken from January
1, 2020 through December 31, 2020, and may be repaid within three years. The repayments will be treated as tax-free rollovers into the
participant’s account.
The Plan Sponsor elected to suspend paying RMDs to participants
and beneficiaries that would otherwise be required to receive an RMD in 2020. However, participants and beneficiaries have a choice between
receiving and not receiving the RMD for 2020. In addition, individuals that received an RMD prior to the enactment of the Act have until
August 31, 2020 to rollover the RMD to an eligible retirement plan.
Plan
Expenses
Substantially
all expenses incurred in connection with the administration of the Plan are paid by the Plan. Costs associated with participant loans
and distribution fees are paid by participants
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
NOTE
2:
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES:
|
Basis
of Accounting
The
Plan’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States
of America and under the accrual basis method of accounting.
Payment
of Benefits
Benefits
are recorded when paid.
Use
of Estimates
The
preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect reported amounts of net assets available for benefits at the date of the financial
statements and the accompanying footnotes and the changes in net assets available for benefits during the reporting period and when applicable
disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.
Investment
Valuation and Income Recognition
The
Plan’s investments are stated at fair value. Fair value is the price that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants at the measurement date. See Note 3 for discussion of fair value measurements.
Interest
income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Investment earnings are reinvested in the respective
funds. Investment earnings include the Plan’s proportionate share of realized gains and losses on the disposal of investments,
and appreciation or depreciation in the fair value of the underlying investments. All purchases and sales are recorded on a trade date
basis.
The
Plan presents in the statement of changes in net asset available for benefits, the net appreciation/depreciation in fair value of its
investments, which consists of the realized gains or losses and the unrealized appreciation/depreciation on those investments
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
NOTE
3:
|
FAIR
VALUE MEASUREMENTS
|
The
Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC” 820), Fair
Value Measurements and Disclosures, provides a framework for measuring fair value. That framework provides a fair value hierarchy
that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted
quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs
(level 3 measurement). The three levels of the fair value hierarchy under ASC 820 are described as follows:
Level
1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan
has the ability to access.
Level
2 - Inputs to the valuation methodology include: quoted prices for similar assets or liabilities in active markets; quoted prices for
identical or similar assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the assets or
liability; inputs that are derived principally from or corroborated by observable market data by correlation or other means.
If
the asset or liability has a specified (contractual) term, the level 2 Input must be observable for substantially the full term of the
asset or liability.
Level
3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurements.
The
asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that
is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the
use of unobservable inputs.
Following
is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies
used at December 31, 2020 and 2019.
Mutual
funds – Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-ended mutual funds that
are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value (“NAV”)
and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
Common
stocks – Enzo Biochem, Inc. – Valued at the closing price reported on the active market on which the individual securities
are traded.
The
methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair
values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants,
the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different
fair value measurement at the reporting date.
The
following tables sets forth by level, within the fair value hierarchy, the Plan’s investments as of December 31:
|
|
Assets at Fair Value
as of
|
|
|
|
2020
|
|
|
2019
|
|
|
|
Level 1
|
|
|
Level 1
|
|
Mutual funds
|
|
$
|
38,527,638
|
|
|
$
|
32,523,374
|
|
Common stock-Enzo Biochem, Inc.
|
|
|
3,376,713
|
|
|
|
2,961,454
|
|
|
|
$
|
41,904,351
|
|
|
$
|
35,484,828
|
|
Changes
in Fair Value Levels
The
availability of observable market data is monitored to assess the appropriate classification of financial instruments within the fair
value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments
from one fair value level to another.
NOTE
4:
|
RIGHT
TO TERMINATE PLAN
|
Although
it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to
terminate the Plan subject to the provisions of ERISA. In the event of Plan termination participants would become 100% vested in their
Company contributions.
The
Plan has adopted the Fidelity Management and Research Company Volume Submitter plan. On March 31, 2014 and June 30, 2020 the Internal
Revenue Service stated in advisory letters that the Volume Submitter adopted by the Plan, as then assigned, was in compliance with the
applicable requirements of the Internal Revenue Code and therefore, the related trust is exempt from taxation. The Plan has been amended
since receiving the letter. However, the Plan administrator believes that the Plan is currently designed and being operated in compliance
with the applicable requirements of the Internal Revenue Code. Therefore, the Plan administrator believes that the Plan is qualified
and the related trust is tax-exempt.
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes
to Financial Statements
Accounting
principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and
recognize a tax liability if the plan has taken an uncertain position that more likely than not would not be sustained upon examination
by a government authority. The plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December
31, 2020, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure
in the financial statements. The Plan is subject to routine examination by taxing jurisdictions; however, there are currently no examinations
for any tax periods in progress.
NOTE
6:
|
RELATED
PARTY AND PARTY IN INTEREST TRANSACTIONS
|
During
2020, the Plan purchased 416,387 shares of common stock of the Plan sponsor, at market prices totaling $1,038,417 and sold 202,450 shares
of common stock at market prices totaling approximately $531,634. At December 31, 2020 and 2019, the Plan held Enzo Biochem, Inc. common
stock with a fair value of $3,376,713 and shares owned of 1,339,965 and a fair value of $2,961,454 and shares owned of 1,126,028, respectively.
Fidelity
Management Trust Company (“FMTC”) is the trustee and record keeper of the Plan. Certain Plan investments are shares of mutual
funds managed by affiliates of FMTC. Therefore, these transactions qualify as Party-in-interest transactions. Fees paid by the Plan for
the investment management services are included in net appreciation in fair value of investments.
Fees
paid by the Plan to FMTC amounted to $27,964 for the year ended December 31, 2020. In addition the Plan paid for legal, advisory and
auditing fees amounting to $28,001 for the year ended December 31, 2020.
NOTE
7:
|
RISKS
AND UNCERTAINTIES
|
The
Plan invests in various investment securities. Investment securities are exposed to various risk such as interest rate, market, and credit
risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the
values of investment securities will occur in the near term and that such changes could materially affect participants’ account
balances and the amounts reported in the statements of net assets available for benefits.
Volatility
in the financial markets may significantly impact the subsequent valuation of the Plan’s investments. Accordingly, the valuation
of investments at December 31, 2020 may not necessarily be indicative of amounts that could be realized in a current market exchange.
The
Company expects that COVID-19 could affect the financial performance of the Plan’s investments throughout 2021. There are a number
of uncertainties that could impact the future financial performance of the Plan’s investments, including the effectiveness of COVID-19
mitigation measures, availability of vaccines; the spread of variations of the virus and the ability of the virus to develop resistance
to existing vaccines; global economic conditions; changes to the Company’s operations; changes in consumer confidence, behaviors
and spending; work from home trends; and the sustainability of supply chains.
ENZO
BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
Investments
in mutual funds are subject to sales charges in the form of front-end loads, back-end loads or 12b-l fees. 12b-l fees, which are ongoing
fees allowable under Section 12b-1 of the Investment Company Act of 1940, are annual fees deducted to pay for marketing and distribution
costs of the funds. These fees are deducted prior to the allocation of the Plan’s investment earnings activity, and thus not separately
identifiable as an expense.
ENZO
BIOCHEM, INC.
SALARY REDUCTION PLAN
Schedule H, Line 4i
Schedule of Assets (Held at End of Year)
E.I.N. # 13-2866202
Plan # 001
December 31, 2020
(a)
|
|
Identity
of Issue, Borrower, Lessor or Similar Party (b)
|
|
Description
of Investment
Including Maturity Date, Rate
of Interest, Collateral, Par or
Maturity Value (c)
|
|
Current
Value (d)
|
|
*
|
|
Enzo
Biochem, Inc.
|
|
Common
Stock
|
|
$
|
3,376,713
|
|
|
|
Pimco
Total Return
|
|
Mutual
Fund
|
|
|
432,509
|
|
|
|
INVS
DIVRS DIVD R5
|
|
Mutual
Fund
|
|
|
380,859
|
|
|
|
NB
Genesis
|
|
Mutual
Fund
|
|
|
937,974
|
|
|
|
JPM
Mid Cap Growth A
|
|
Mutual
Fund
|
|
|
756,168
|
|
|
|
WF
SPL Small Cap Val A
|
|
Mutual
Fund
|
|
|
247,444
|
|
|
|
Columbia
Acorn International Select
|
|
Mutual
Fund
|
|
|
267,983
|
|
|
|
TRP
Div Growth Adv
|
|
Mutual
Fund
|
|
|
136,255
|
|
|
|
Parnassus
Mid Cap
|
|
Mutual
Fund
|
|
|
140,801
|
|
*
|
|
Fidelity
Contrafund
|
|
Mutual
Fund
|
|
|
3,157,426
|
|
*
|
|
Fidelity
Capital & Income
|
|
Mutual
Fund
|
|
|
990,154
|
|
*
|
|
Fidelity
Government Income
|
|
Mutual
Fund
|
|
|
313,647
|
|
*
|
|
Fidelity
International Discovery
|
|
Mutual
Fund
|
|
|
323,796
|
|
*
|
|
Fidelity
Emerging Markets
|
|
Mutual
Fund
|
|
|
756,347
|
|
*
|
|
Fidelity
Growth Discovery
|
|
Mutual
Fund
|
|
|
3,044,269
|
|
*
|
|
Fidelity
Freedom Income
|
|
Mutual
Fund
|
|
|
634
|
|
*
|
|
Fidelity
Freedom Inc
|
|
Mutual
Fund
|
|
|
78,149
|
|
*
|
|
Fidelity
Freedom 2010
|
|
Mutual
Fund
|
|
|
634,087
|
|
*
|
|
Fidelity
Freedom 2020
|
|
Mutual
Fund
|
|
|
3,606,587
|
|
*
|
|
Fidelity
Freedom 2030
|
|
Mutual
Fund
|
|
|
3,961,249
|
|
*
|
|
Fidelity
Ext Market Inx
|
|
Mutual
Fund
|
|
|
1,084,705
|
|
*
|
|
Fidelity
International Index
|
|
Mutual
Fund
|
|
|
231,437
|
|
*
|
|
Fidelity
Govt MMKT
|
|
Mutual
Fund
|
|
|
2,235,925
|
|
*
|
|
Fidelity
500 Index
|
|
Mutual
Fund
|
|
|
1,772,755
|
|
*
|
|
Fidelity
Freedom 2040
|
|
Mutual
Fund
|
|
|
1,890,046
|
|
*
|
|
Fidelity
Freedom 2005
|
|
Mutual
Fund
|
|
|
102,475
|
|
*
|
|
Fidelity
Freedom 2015
|
|
Mutual
Fund
|
|
|
2,817,095
|
|
*
|
|
Fidelity
Freedom 2025
|
|
Mutual
Fund
|
|
|
3,020,084
|
|
*
|
|
Fidelity
Freedom 2035
|
|
Mutual
Fund
|
|
|
2,385,247
|
|
*
|
|
Fidelity
Freedom 2045
|
|
Mutual
Fund
|
|
|
1,133,176
|
|
*
|
|
Fidelity
Freedom 2050
|
|
Mutual
Fund
|
|
|
695,258
|
|
*
|
|
Fidelity
US Bond IDX Adv
|
|
Mutual
Fund
|
|
|
442,534
|
|
*
|
|
Fidelity
Freedom 2055
|
|
Mutual
Fund
|
|
|
367,770
|
|
*
|
|
Fidelity
Freedom 2060
|
|
Mutual
Fund
|
|
|
180,992
|
|
*
|
|
Fidelity
Freedom 2065
|
|
Mutual
Fund
|
|
|
727
|
|
*
|
|
Fidelity
Cash Reserves
|
|
Mutual
Fund
|
|
|
1,074
|
|
*
|
|
Notes
receivable – participants(e)
|
|
4.5%
- 5.0%
|
|
|
582,320
|
|
|
|
|
|
|
|
$
|
42,486,671
|
|
*
|
Party-in-interest,
as defined by ERISA
|
(e)
|
Participant
notes receivable mature from January 2021 through December 2026.
|
EXHIBIT INDEX
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, a trustee of the below named employee benefit plan has duly caused this annual
report to be signed on its behalf by the undersigned hereunto duly authorized.
Enzo
Biochem, Inc. Salary Reduction Profit Sharing Plan
Date:
June 25, 2021
|
|
|
|
/s/
Barry Weiner
|
|
By:
Barry Weiner
|
|
Trustee
|
|
13
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024